ChemoCentryx, Inc. (CCXI): Price and Financial Metrics


ChemoCentryx, Inc. (CCXI): $22.39

0.68 (+3.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CCXI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CCXI POWR Grades


  • CCXI scores best on the Growth dimension, with a Growth rank ahead of 75.75% of US stocks.
  • The strongest trend for CCXI is in Growth, which has been heading up over the past 179 days.
  • CCXI's current lowest rank is in the Stability metric (where it is better than 9.26% of US stocks).

CCXI Stock Summary

  • With a price/sales ratio of 56.52, ChemoCentryx Inc has a higher such ratio than 96.45% of stocks in our set.
  • Revenue growth over the past 12 months for ChemoCentryx Inc comes in at -50.34%, a number that bests only 3.17% of the US stocks we're tracking.
  • The volatility of ChemoCentryx Inc's share price is greater than that of 90.76% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ChemoCentryx Inc are HRTX, DBX, ADCT, QLGN, and CLSN.
  • CCXI's SEC filings can be seen here. And to visit ChemoCentryx Inc's official web site, go to www.chemocentryx.com.

CCXI Valuation Summary

  • CCXI's EV/EBIT ratio is -9.1; this is 131.06% lower than that of the median Healthcare stock.
  • CCXI's price/sales ratio has moved up 40 over the prior 116 months.
  • CCXI's price/earnings ratio has moved up 116.3 over the prior 116 months.

Below are key valuation metrics over time for CCXI.

Stock Date P/S P/B P/E EV/EBIT
CCXI 2021-08-31 51.1 3.3 -9.0 -9.1
CCXI 2021-08-30 49.9 3.3 -8.8 -8.9
CCXI 2021-08-27 50.9 3.3 -9.0 -9.1
CCXI 2021-08-26 50.0 3.3 -8.8 -8.9
CCXI 2021-08-25 49.0 3.2 -8.6 -8.8
CCXI 2021-08-24 48.1 3.1 -8.5 -8.6

CCXI Growth Metrics

    The year over year revenue growth rate now stands at 104.79%.
  • Its year over year net cashflow from operations growth rate is now at 5.07%.
  • Its 2 year net cashflow from operations growth rate is now at -501.51%.
CCXI's revenue has moved up $3,182,000 over the prior 49 months.

The table below shows CCXI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 34.267 -83.958 -121.103
2021-06-30 21.609 -74.797 -122.856
2021-03-31 69.236 -75.264 -63.38
2020-12-31 64.891 -81.143 -55.356
2020-09-30 70.58 -82.149 -41.008
2020-06-30 76.076 -82.726 -29.81

CCXI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CCXI has a Quality Grade of D, ranking ahead of 9.23% of graded US stocks.
  • CCXI's asset turnover comes in at 0.043 -- ranking 329th of 682 Pharmaceutical Products stocks.
  • LUMO, CBAY, and BPTH are the stocks whose asset turnover ratios are most correlated with CCXI.

The table below shows CCXI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.043 1 -0.262
2021-03-31 0.132 1 -0.148
2020-12-31 0.145 1 -0.163
2020-09-30 0.191 1 -0.166
2020-06-30 0.262 1 -0.190
2020-03-31 0.159 1 -0.476

CCXI Price Target

For more insight on analysts targets of CCXI, see our CCXI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.50 Average Broker Recommendation 1.31 (Strong Buy)

CCXI Stock Price Chart Interactive Chart >

Price chart for CCXI

CCXI Price/Volume Stats

Current price $22.39 52-week high $42.16
Prev. close $21.71 52-week low $9.75
Day low $21.57 Volume 716,712
Day high $22.58 Avg. volume 1,416,369
50-day MA $21.44 Dividend yield N/A
200-day MA $26.74 Market Cap 1.59B

ChemoCentryx, Inc. (CCXI) Company Bio


ChemoCentryx, Inc. focuses on the discovery, development, and commercialization of orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. The company was founded in 1997 and is based in Mountain View, California.


CCXI Latest News Stream


Event/Time News Detail
Loading, please wait...

CCXI Latest Social Stream


Loading social stream, please wait...

View Full CCXI Social Stream

Latest CCXI News From Around the Web

Below are the latest news stories about ChemoCentryx Inc that investors may wish to consider to help them evaluate CCXI as an investment opportunity.

ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022

MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-

Yahoo | February 23, 2022

ChemoCentryx (CCXI) Receives a Buy from H.C. Wainwright

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on ChemoCentryx (CCXI – Research Report), with a price target of $101.00. The company's shares closed last Tuesday at $31.51. According to TipRanks.com, White 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.4% and a 32.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Aeglea Biotherapeutics. ChemoCentryx has an analyst consensus of Strong Buy, with a price target consensus of $62.75, implying a 101.9% upside from current levels.

Brian Anderson on TipRanks | February 15, 2022

ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

SAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 th at 5:00 p.m. Eastern Time.

GlobeNewswire | February 9, 2022

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -30.97% and 3.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 8, 2022

Lisanti Capital Growth, LLC Buys Saia Inc, Knight-Swift Transportation Holdings Inc, ...

Investment company Lisanti Capital Growth, LLC (Current Portfolio) buys Saia Inc, Knight-Swift Transportation Holdings Inc, Cytokinetics Inc, ArcBest Corp, Inspire Medical Systems Inc, sells CommVault Systems Inc, Varonis Systems Inc, Sprout Social Inc, Acadia Healthcare Co Inc, Crocs Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Lisanti Capital Growth, LLC.

Yahoo | February 4, 2022

Read More 'CCXI' Stories Here

CCXI Price Returns

1-mo 16.68%
3-mo -26.90%
6-mo -38.29%
1-year 129.17%
3-year 91.20%
5-year 224.49%
YTD -38.51%
2021 -41.20%
2020 56.56%
2019 262.51%
2018 83.36%
2017 -19.59%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6372 seconds.